2-(2-Nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2-Nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione
• 英文别名: 2-[4-(fluoromethyl)-2-nitrobenzoyl]cyclohexane-1,3-dione
• 化学式: C14H12FNO5
• 分子量: 293.25
• InChiKey: XHYUTFGYDSYPCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  97
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• METHODS OF DIFFERENTIATING STEM CELLS INTO LIVER CELL LINEAGES
  申请人：Agency for Science, Technology and Research

  公开号：EP3204489A1

  公开（公告）日：2017-08-16
• THERAPEUTIC COMPOSITIONS COMPRISING TRANSCRIPTION FACTORS AND METHODS OF MAKING AND USING THE SAME
  申请人：The Regents of the University of California

  公开号：EP3224362A2

  公开（公告）日：2017-10-04
• PATCH GRAFTING OF STEM/PROGENITORS INTO SOLID ORGANS
  申请人：The University of North Carolina at Chapel Hill

  公开号：EP3976122A1

  公开（公告）日：2022-04-06
• GENERATING HEPATOCYTES
  申请人：Zhu Saiyong

  公开号：US20150175962A1

  公开（公告）日：2015-06-25

  Compositions and methods are described herein for inducing reprogramming of non-pluripotent cells across lineage and differentiation boundaries to generate endodermal progenitor cells and hepatocytes. Compositions and methods for expansion of endodermal progenitor cells without loss of phenotype are also described herein.
• HYBRID VIRUS-LIKE PARTICLES AND USE THEREOF AS A THERAPEUTIC HEPATITIS B VACCINE
  申请人：VLP Biotech, Inc.

  公开号：US20220411475A1

  公开（公告）日：2022-12-29

  The present disclosure relates to hybrid hepadnavirus core antigens including one or more epitopes of a human hepatitis B vims (HBV) antigen. More specifically, the present disclosure relates to hybrid hepadnavirus core antigens in the form of fusion proteins containing a fragment of the PreS1 region of the HBV surface antigen inserted in a woodchuck hepadnavirus core antigen. The present disclosure further relates to hybrid hepadnavirus core antigens in the form of fusions proteins containing a truncated HBV core antigen and woodchuck hepadnavirus core antigen. Also provided are nucleic acids encoding the hybrid core antigens, and the use of the hybrid core antigens and nucleic acids for treating HBV-infected individuals.